ALK-Abello A/S Series B | Income Statement

Fiscal year is January-December. All values DKK Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,244
2,433
2,569
3,005
2,910
2,915
Cost of Goods Sold (COGS) incl. D&A
759
793
897
1,066
1,177
1,335
Gross Income
1,485
1,640
1,672
1,939
1,733
1,580
SG&A Expense
1,355
1,328
1,378
1,467
1,662
1,664
EBIT
129
312
294
-
71
84
Unusual Expense
22
52
39
-
160
45
Non Operating Income/Expense
8
53
156
16
34
39
Interest Expense
11
15
14
14
16
25
Pretax Income
104
300
400
487
122
103
Income Tax
43
119
56
217
36
67
Consolidated Net Income
61
181
344
270
158
170
Net Income
61
181
344
270
158
170
Net Income After Extraordinaries
61
181
344
270
158
170
Net Income Available to Common
61
181
344
270
158
170
EPS (Basic)
6.31
18.74
35.45
27.51
15.93
15.64
Basic Shares Outstanding
10
10
10
10
10
11
EPS (Diluted)
6.24
18.32
34.95
27.24
15.93
15.64
Diluted Shares Outstanding
10
10
10
10
10
11
EBITDA
256
452
452
635
252
109
Other Operating Expense
1
-
-
-
-
-
Non-Operating Interest Income
-
2
3
13
17
12

About ALK-Abello A/S

View Profile
Address
Bøge Allé 6-8
Hørsholm CR 2970
Denmark
Employees -
Website http://www.alk.net
Updated 07/08/2019
ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. It also manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics.